Our observation that Nedd9-depleted CLL cells showed decreased level of CTTN together with the potency of AURKA and/or HDAC6 inhibitors to reduce CLL migration in a NEDD9-dependent manner strongly suggests a similar mode of action in CLL. The gene discussed is HDAC6; the disease is B-cell chronic lymphocytic leukemia.